大剂量沐舒坦治疗重型颅脑损伤后肺部感染疗效分析

Analysis of therapeutic effect of large-dose ambroxol in pulmonary infection after severe craniocerebral injury

目的探讨重型颅脑损伤患者合并肺部感染的治疗。方法重型颅脑损伤后肺部感染的患者300例,随机选150例(实验组)在原有治疗的基础上静滴大剂量沐舒坦,另150例(对照组)静滴小剂量沐舒坦,所有患者其他治疗措施均基本相同。结果实验组有141例感染控制,感染控制时间平均天数为(7.5±2.2)d;对照组有122例感染控制,感染控制时间平均天数为(12.3±2.2)d。实验组肺部感染控制率显著高于对照组(P<0.05),而控制感染平均时间显著短于对照组(P<0.05)。结论对于重型颅脑损伤除进行综合治疗外,推荐使用沐舒坦预防和控制肺部感染。

Objective To investigate the treatment in patients with severe craniocerebral injury and pulmonary infection. Methods 300 patients with pulmonary infection after severe craniocerebral injury were selected. 150 patients randomly selected（ experimental group） were treated with intravenous infusion of large-dose ambroxol based on the original treatment. The other 150 patients（ control group） were treated with intravenous infusion of low-dose ambroxol. The other treatments in all patients were basicly the same. Results 141 cases in experimental group were under infection control and the mean days of infection control were（7.5 ±2.2）days; 122 cases in control group were under infection control and the mean days of infection control were（ 12.3 ±2.2） days. The rate of pulmonary infection control in experimental group was sig- nificantly higher than that in control group（P 〈 0.05 ） ; the mean days of infection control in experimental group were significantly less than that in control group（P 〈 0.05 ）. Conclusion In addition to the comprehensive treatment in severe craniocerebral injury, amroxol is recommended to prevent and control pulmonary infection.